| 产品编号 | bsm-52912R |
| 英文名称 | CD41/ITGA2B Recombinant Rabbit mAb |
| 中文名称 | 血小板膜糖蛋白Ⅱb（CD41）重组兔单抗 |
| 别 名 | platelet glycoprotein IIb of IIb/IIIa complex; Integrin, alpha 2b(platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41); GPIIb; GTA; HPA3; CD 41; CD41 antigen; CD41a; CD41b; GP2b; GPalpha IIb; GPalphaIIb; Integrin alpha IIb; Integrin alpha IIb precursor; ITGA 2B; Integrin alpha 2b; ITGAB; Platelet fibrinogen receptor alpha; Platelet fibrinogen receptor alpha subunit; Platelet glycoprotein IIb of IIb/IIIa complex; Platelet membrane glycoprotein IIb; Platelet specific antigen bak; ITA2B_HUMAN. |
| 研究领域 | 心血管 细胞生物 免疫学 信号转导 干细胞 细胞粘附分子 |
| 抗体来源 | Rabbit |
| 克隆类型 | Recombinant |
| 克 隆 号 | 7C8 |
| 交叉反应 | Human |
| 产品应用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 113 kDa |
| 检测分子量 | |
| 细胞定位 | 细胞膜 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | A synthesized peptide derived from human Integrin alpha 2b: 50-100 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
This gene encodes a member of the integrin alpha chain family of proteins. The encoded preproprotein is proteolytically processed to generate light and heavy chains that associate through disulfide linkages to form a subunit of the alpha-IIb/beta-3 integrin cell adhesion receptor. This receptor plays a crucial role in the blood coagulation system, by mediating platelet aggregation. Mutations in this gene are associated with platelet-type bleeding disorders, which are characterized by a failure of platelet aggregation, including Glanzmann thrombasthenia. [provided by RefSeq, Jan 2016] Function: Isoform 1 and isoform 2 were identified in platelets and megakaryocytes, but not in reticulocytes or in Jurkat and U937 white blood cell line. Isoform 3 is expressed by leukemia, prostate adenocarcinoma and melanoma cells but not by platelets or normal prostate or breast epithelial cells. Subcellular Location: Membrane. DISEASE: Defects in ITGA2B are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. GT is the most common inherited disease of platelets. It is an autosomal recessive disorder characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb/beta-3 complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the glycoprotein IIb/beta-3 complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT 'variants' have normal or near normal (60-100%) expression of dysfunctional receptors. Similarity: Belongs to the integrin alpha chain family. Contains 7 FG-GAP repeats. SWISS: P08514 Gene ID: 3674 Database links: Entrez Gene: 3674 Human Entrez Gene: 16399 Mouse Entrez Gene: 685269 Rat Omim: 607759 Human SwissProt: P08514 Human SwissProt: Q9QUM0 Mouse Unigene: 411312 Human Unigene: 26646 Mouse Unigene: 128177 Rat |
| 产品图片 |
Paraformaldehyde-fixed, paraffin embedded Human Spleen; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; The section was incubated with CD41/ITGA2B Monoclonal Antibody, Unconjugated (bsm-52912R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
